Murthy Simhambhatla

Murthy Simhambhatla has served as President and Chief Executive Officer of SetPoint Medical since 2018. Prior to his tenure at SetPoint Medical, he was President and Chief Executive Officer of Evolus, a medical aesthetics company that he guided towards an initial public offering (IPO).

Before Evolus, Murthy held the position of Senior Vice President at Abbott and President of Abbott Medical Optics (AMO), a $1B-plus global ophthalmic business focused on cataract and refractive surgery.

Prior to his role at AMO, Murthy led the Ibis Biosciences molecular diagnostics unit at Abbott. He joined Abbott through the acquisition of Guidant’s vascular division, where he led the development of the Xience V® Drug Eluting Stent, which remains the leading vascular stent platform globally.

Murthy is a Fellow of the American Institute for Medical and Biological Engineering.